Delirium is a Potential Predictor of Unfavorable Long-term Functional Outcomes in Patients with Acute Ischemic Stroke: A Prospective Observational Study.
{"title":"Delirium is a Potential Predictor of Unfavorable Long-term Functional Outcomes in Patients with Acute Ischemic Stroke: A Prospective Observational Study.","authors":"Chenhui Lin, Heyu Zhang, Fangyi Xiao, Yujie Tu, Yaoyao Lin, Luqian Zhan, Yisi Lin, Yanwei Li, Chenglong Xie, Yanyan Chen","doi":"10.2147/JIR.S505038","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Delirium is an acute fluctuating impairment of attention and awareness, common in acute ischemic stroke (AIS). This study aimed to evaluate the prognostic significance of delirium for neurological function at 3 months post-stroke, and develop a predictive model integrating delirium and biomarkers to enhance prognostic accuracy.</p><p><strong>Methods: </strong>We conducted a prospective cohort study of patients admitted to the stroke unit (n=722). All patients were screened for daily delirium during clinical care. Plasma biomarkers were measured within 24 hours after admission. The main outcomes were evaluated with the 3-months modified Rankin Scale (mRS).</p><p><strong>Results: </strong>Delirium developed in 10.2% of patients during the acute phase of stroke. Patients with post-stroke delirium (PSD) was significantly older (median age 74 vs 68 years, <i>P</i><0.001), more likely to have pre-stroke cognitive impairment (14.9% vs 4.8%, <i>P</i>=0.001), a higher prevalence of cardiovascular history (35.1% vs 16.2%, <i>P</i><0.001). PSD was also associated with higher scores of NIHSS (14.3 vs 9.1, <i>P</i><0.001) and greater scores of mRS (3.0 vs 1.5, <i>P</i><0.001) at admission. PSD patients showed worse outcomes, with elevated NIHSS and mRS scores at discharge and 3-month follow-up, as well as higher mortality rates (5.4% vs 1.4%, <i>P</i>=0.025). Biomarker analysis revealed increased plasma levels of inflammatory (white blood cells, neutrophils, C-reactive protein) and coagulation biomarkers (fibrinogen, D-dimer) in PSD patients, particularly those with poorer outcomes (<i>P</i><0.01). Our model, which incorporated delirium and biomarkers of inflammation and coagulation dysfunction, demonstrated strong predictive accuracy for adverse outcomes at 3 months with an AUC of 0.779 (95% CI=0.736-0.822), with clinical utility confirmed by decision curve analysis.</p><p><strong>Conclusion: </strong>PSD is a strong independent predictor of poor 3-month outcomes in AIS, including higher mortality and disability. Our findings highlight the critical role of inflammation and coagulation dysfunction in the pathogenesis of PSD. Furthermore, we present the clinical utility of a predictive model integrating delirium and relevant biomarkers to assess the risk of adverse outcomes at 3 months, suggesting potential targets for intervention.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"4019-4035"},"PeriodicalIF":4.2000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929518/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Inflammation Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JIR.S505038","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Delirium is an acute fluctuating impairment of attention and awareness, common in acute ischemic stroke (AIS). This study aimed to evaluate the prognostic significance of delirium for neurological function at 3 months post-stroke, and develop a predictive model integrating delirium and biomarkers to enhance prognostic accuracy.
Methods: We conducted a prospective cohort study of patients admitted to the stroke unit (n=722). All patients were screened for daily delirium during clinical care. Plasma biomarkers were measured within 24 hours after admission. The main outcomes were evaluated with the 3-months modified Rankin Scale (mRS).
Results: Delirium developed in 10.2% of patients during the acute phase of stroke. Patients with post-stroke delirium (PSD) was significantly older (median age 74 vs 68 years, P<0.001), more likely to have pre-stroke cognitive impairment (14.9% vs 4.8%, P=0.001), a higher prevalence of cardiovascular history (35.1% vs 16.2%, P<0.001). PSD was also associated with higher scores of NIHSS (14.3 vs 9.1, P<0.001) and greater scores of mRS (3.0 vs 1.5, P<0.001) at admission. PSD patients showed worse outcomes, with elevated NIHSS and mRS scores at discharge and 3-month follow-up, as well as higher mortality rates (5.4% vs 1.4%, P=0.025). Biomarker analysis revealed increased plasma levels of inflammatory (white blood cells, neutrophils, C-reactive protein) and coagulation biomarkers (fibrinogen, D-dimer) in PSD patients, particularly those with poorer outcomes (P<0.01). Our model, which incorporated delirium and biomarkers of inflammation and coagulation dysfunction, demonstrated strong predictive accuracy for adverse outcomes at 3 months with an AUC of 0.779 (95% CI=0.736-0.822), with clinical utility confirmed by decision curve analysis.
Conclusion: PSD is a strong independent predictor of poor 3-month outcomes in AIS, including higher mortality and disability. Our findings highlight the critical role of inflammation and coagulation dysfunction in the pathogenesis of PSD. Furthermore, we present the clinical utility of a predictive model integrating delirium and relevant biomarkers to assess the risk of adverse outcomes at 3 months, suggesting potential targets for intervention.
目的:谵妄是一种注意力和意识的急性波动障碍,常见于急性缺血性卒中(AIS)。本研究旨在评估谵妄对脑卒中后3个月神经功能的预后意义,并建立一种结合谵妄和生物标志物的预测模型,以提高预后准确性。方法:我们对卒中病房收治的患者进行了一项前瞻性队列研究(n=722)。在临床护理期间对所有患者进行日常谵妄筛查。入院后24小时内测定血浆生物标志物。采用3个月改良Rankin量表(mRS)评价主要结局。结果:10.2%的患者在脑卒中急性期出现谵妄。卒中后谵妄(PSD)患者明显年龄较大(中位年龄74 vs 68岁,PP=0.001),心血管病史患病率较高(35.1% vs 16.2%, PPPP=0.025)。生物标志物分析显示,PSD患者的血浆炎症(白细胞、中性粒细胞、c反应蛋白)和凝血生物标志物(纤维蛋白原、d -二聚体)水平升高,尤其是那些预后较差的患者。结论:PSD是AIS患者3个月预后较差的一个强有力的独立预测指标,包括较高的死亡率和致残率。我们的研究结果强调了炎症和凝血功能障碍在PSD发病机制中的关键作用。此外,我们提出了一种结合谵妄和相关生物标志物的预测模型的临床应用,以评估3个月时不良后果的风险,提出了干预的潜在目标。
期刊介绍:
An international, peer-reviewed, open access, online journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation.